摘要
目的分析弥漫大B细胞淋巴瘤(Diffuse Large B-cell Lymphoma,DLBCL)患者微小RNA-125(microRNA-125,miR-125)表达水平与临床病理参数及预后的关系。方法回顾性分析2015年3月-2017年3月四川大学华西医院血液内科收治的148例DLBCL患者的临床资料,列为DLBCL组。取同期收治的淋巴结反应性增生(Reactive Hyperplasia of Lymph Node,RH)患者35例列为对照组,采用实时荧光定量聚合酶链方法(Real-Time Reverse Transcription Polymerase Chain Reaction,RT-PCR)检测组织标本miR-125表达,分析其与DLBCL病理特点及预后的关系。结果DLBCL组组织miR-125表达水平(3.514±1.101)明显高于对照组(0.362±0.097,P<0.05),差异有统计学意义;免疫表型、乳酸脱氢酶水平、IPI评分与Ki-67指数均为miR-125表达相关影响因素(P<0.05);免疫表型为非生发中心来源、Ann Arbor临床分期为Ⅲ~Ⅳ期、乳酸脱氢酶>245 U/L、国际预后指数(International Prognostic Index,IPI)评分3~5分、结外累及≥2处、Ki-67指数≥75%的DLBCL患者miR-125表达水平更高(P<0.05);低miR-125表达组总生存率为97.4%,中位生存时间为36.30个月;高miR-125表达组总生存率为77.1%,中位生存时间为33.67个月,两组生存情况比较(Log Rankχ^2=4.488,P=0.034<0.05)。结论DLBCL组组织miR-125呈异常高表达,且与免疫表型、乳酸脱氢酶水平、IPI评分及Ki-67指数有关,参与DLBCL发病及进展过程,且对预后存在一定的影响。
Objective To analyze the relationship of microRNA-125(miR-125) expression level with clinicopathological parameters and prognosis of patients with diffuse large B-cell lymphoma(DLBCL).Methods The clinical data of 148 patients with DLBCL admitted to the department of hematology at West China Hospital of Sichuan University from March 2015 to March 2017 were retrospectively analyzed.Meanwhile,35 patients with reactive hyperplasia of lymph node(RH) were recruited as control group.The expression of miR-125 in tissue samples was detected by real-time reverse transcription polymerase chain reaction(RT-PCR),and its relationship with pathological features and prognosis of DLBCL was analyzed.Results The expression level of miR-125 in DLBCL group was(3.514± 1.101),significantly higher than(0.362 ± 0.097) in the control group(P <0.05).suggested that immunophenotype,lactate dehydrogenase level,IPI score and Ki-67 index were related factors influencing miR-125 expression(P <0.05).Suggested that immunophenotype,lactate dehydrogenase level,IPI score and Ki-67 index were related factors influencing miR-125 expression(P<0.05).In DLBCL group,patients with non-germinal center B-cell like immunophenotype,in Ann Arbor clinical stage Ⅲ~Ⅳ,with lactate dehydrogenase higher than 245 U/L,with international prognostic index(IPI) score of 3 ~ 5 points,with two or more sites of extranodal involvement,and Ki-67 index not lower than 75% had higher expression level of miR-125(P<0.05).The overall survival rate and median survival time of low miR-125 expression group were 97.1% and 36.30 months,which of high miR-125 expression group were 82.1% and 36 months,showing statistically significant differences in survival status between the two groups(Log Rank χ~2= 4.488,P =0.034<0.05).Conclusion Patients with DLBCL have abnormally high expression level of miR-125,while the expression level is related to immunophenotype,lactate dehydrogenase level,IPI score and Ki-67 index.It not only participates in the pathogenesis and progression of DLBCL but al
作者
兰坚
杨蜀锦
李妮
王娇
LAN Jian;YANG Shujin;LI Ni;WANG Jiao(Department of Hematology,West China Hospital,Sichuan University,Chengdu Sichuan 610041,China;Department of Oncology,Chengdu Seventh People′s Hospital,Chengdu Sichuan 610000,China)
出处
《转化医学杂志》
2021年第1期35-39,共5页
Translational Medicine Journal
